187 related articles for article (PubMed ID: 37542379)
1. Neutralizing antibodies against EBV gp42 show potent
Wu Q; Zhong L; Wei D; Zhang W; Hong J; Kang Y; Chen K; Huang Y; Zheng Q; Xu M; Zeng MS; Zeng YX; Xia N; Zhao Q; Krummenacher C; Chen Y; Zhang X
Emerg Microbes Infect; 2023 Dec; 12(2):2245920. PubMed ID: 37542379
[TBL] [Abstract][Full Text] [Related]
2. Non-overlapping epitopes on the gHgL-gp42 complex for the rational design of a triple-antibody cocktail against EBV infection.
Hong J; Zhong L; Liu L; Wu Q; Zhang W; Chen K; Wei D; Sun H; Zhou X; Zhang X; Kang YF; Huang Y; Chen J; Wang G; Zhou Y; Chen Y; Feng QS; Yu H; Li S; Zeng MS; Zeng YX; Xu M; Zheng Q; Chen Y; Zhang X; Xia N
Cell Rep Med; 2023 Nov; 4(11):101296. PubMed ID: 37992686
[TBL] [Abstract][Full Text] [Related]
3. Antibody Generation and Immunogenicity Analysis of EBV gp42 N-Terminal Region.
Hong J; Wei D; Wu Q; Zhong L; Chen K; Huang Y; Zhang W; Chen J; Xia N; Zhang X; Chen Y
Viruses; 2021 Nov; 13(12):. PubMed ID: 34960650
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus gp42 antibodies reveal sites of vulnerability for receptor binding and fusion to B cells.
Bu W; Kumar A; Board NL; Kim J; Dowdell K; Zhang S; Lei Y; Hostal A; Krogmann T; Wang Y; Pittaluga S; Marcotrigiano J; Cohen JI
Immunity; 2024 Mar; 57(3):559-573.e6. PubMed ID: 38479361
[TBL] [Abstract][Full Text] [Related]
5. Potent human monoclonal antibodies targeting Epstein-Barr virus gp42 reveal vulnerable sites for virus infection.
Zhao GX; Fang XY; Bu GL; Chen SJ; Sun C; Li T; Xie C; Wang Y; Li SX; Meng N; Feng GK; Zhong Q; Kong XW; Liu Z; Zeng MS
Cell Rep Med; 2024 May; 5(5):101573. PubMed ID: 38776874
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of EBV-mediated membrane fusion by anti-gHgL antibodies.
Sathiyamoorthy K; Jiang J; Möhl BS; Chen J; Zhou ZH; Longnecker R; Jardetzky TS
Proc Natl Acad Sci U S A; 2017 Oct; 114(41):E8703-E8710. PubMed ID: 28939750
[TBL] [Abstract][Full Text] [Related]
7. Membrane anchoring of Epstein-Barr virus gp42 inhibits fusion with B cells even with increased flexibility allowed by engineered spacers.
Rowe CL; Chen J; Jardetzky TS; Longnecker R
mBio; 2015 Jan; 6(1):. PubMed ID: 25564465
[TBL] [Abstract][Full Text] [Related]
8. Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells.
Bu W; Joyce MG; Nguyen H; Banh DV; Aguilar F; Tariq Z; Yap ML; Tsujimura Y; Gillespie RA; Tsybovsky Y; Andrews SF; Narpala SR; McDermott AB; Rossmann MG; Yasutomi Y; Nabel GJ; Kanekiyo M; Cohen JI
Immunity; 2019 May; 50(5):1305-1316.e6. PubMed ID: 30979688
[TBL] [Abstract][Full Text] [Related]
9. A Neutralizing Antibody Targeting gH Provides Potent Protection against EBV Challenge
Hong J; Zhong L; Zheng Q; Wu Q; Zha Z; Wei D; Chen H; Zhang W; Zhang S; Huang Y; Chen K; Chen J; Li S; Zeng MS; Zeng YX; Xia N; Zhang X; Xu M; Chen Y
J Virol; 2022 Apr; 96(8):e0007522. PubMed ID: 35348362
[TBL] [Abstract][Full Text] [Related]
10. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
[TBL] [Abstract][Full Text] [Related]
11. A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice.
Wei CJ; Bu W; Nguyen LA; Batchelor JD; Kim J; Pittaluga S; Fuller JR; Nguyen H; Chou TH; Cohen JI; Nabel GJ
Sci Transl Med; 2022 May; 14(643):eabf3685. PubMed ID: 35507671
[TBL] [Abstract][Full Text] [Related]
12. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.
Zhang X; Zhao B; Ding M; Song S; Kang Y; Yu Y; Xu M; Xiang T; Gao L; Feng Q; Zhao Q; Zeng MS; Krummenacher C; Zeng YX
Theranostics; 2020; 10(13):5704-5718. PubMed ID: 32483413
[No Abstract] [Full Text] [Related]
13. Binding-site interactions between Epstein-Barr virus fusion proteins gp42 and gH/gL reveal a peptide that inhibits both epithelial and B-cell membrane fusion.
Kirschner AN; Lowrey AS; Longnecker R; Jardetzky TS
J Virol; 2007 Sep; 81(17):9216-29. PubMed ID: 17581996
[TBL] [Abstract][Full Text] [Related]
14. The Cytoplasmic Tail Domain of Epstein-Barr Virus gH Regulates Membrane Fusion Activity through Altering gH Binding to gp42 and Epithelial Cell Attachment.
Chen J; Jardetzky TS; Longnecker R
mBio; 2016 Nov; 7(6):. PubMed ID: 27935841
[TBL] [Abstract][Full Text] [Related]
15. A cocktail nanovaccine targeting key entry glycoproteins elicits high neutralizing antibody levels against EBV infection.
Zhong L; Zhang W; Liu H; Zhang X; Yang Z; Wen Z; Chen L; Chen H; Luo Y; Chen Y; Feng Q; Zeng MS; Zhao Q; Liu L; Krummenacher C; Zeng YX; Chen Y; Xu M; Zhang X
Nat Commun; 2024 Jun; 15(1):5310. PubMed ID: 38906867
[TBL] [Abstract][Full Text] [Related]
16. Soluble Epstein-Barr virus glycoproteins gH, gL, and gp42 form a 1:1:1 stable complex that acts like soluble gp42 in B-cell fusion but not in epithelial cell fusion.
Kirschner AN; Omerovic J; Popov B; Longnecker R; Jardetzky TS
J Virol; 2006 Oct; 80(19):9444-54. PubMed ID: 16973550
[TBL] [Abstract][Full Text] [Related]
17. Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay.
Sashihara J; Burbelo PD; Savoldo B; Pierson TC; Cohen JI
Virology; 2009 Sep; 391(2):249-56. PubMed ID: 19584018
[TBL] [Abstract][Full Text] [Related]
18. Cleavage and secretion of Epstein-Barr virus glycoprotein 42 promote membrane fusion with B lymphocytes.
Sorem J; Jardetzky TS; Longnecker R
J Virol; 2009 Jul; 83(13):6664-72. PubMed ID: 19369343
[TBL] [Abstract][Full Text] [Related]
19. A potent and protective human neutralizing antibody targeting a novel vulnerable site of Epstein-Barr virus.
Zhu QY; Shan S; Yu J; Peng SY; Sun C; Zuo Y; Zhong LY; Yan SM; Zhang X; Yang Z; Peng YJ; Shi X; Cao SM; Wang X; Zeng MS; Zhang L
Nat Commun; 2021 Nov; 12(1):6624. PubMed ID: 34785638
[TBL] [Abstract][Full Text] [Related]
20. A novel high throughput assay to quantify Epstein-Barr virus neutralizing antibody activity against B-cell and epithelial cell infections for vaccine and therapeutic developments.
Li F; Freed D; Heidecker G; Galli J; Durr E; Wang D
Vaccine; 2022 Jun; 40(26):3638-3646. PubMed ID: 35577627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
